# Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

> clinical trial · VERIFIED · 2026-07-09

Status: COMPLETED · Sponsor: Merck Sharp & Dohme LLC · Condition: Prostatic Neoplasms

- Company: Merck Sharp & Dohme LLC
- Sector: Prostatic Neoplasms
- Primary source: https://clinicaltrials.gov/study/NCT03834493

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.